Limitations, agreements, and source contact

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies · Source last updated 2013-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

hingwong@altorbioscience.com

organization

Altor Bioscience

phone

9544438600

title

Hing C. Wong, Chief Clinical Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice